Penn spinout Interius BioTherapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor in the Division of Hematology and Oncology at Penn Medicine, has dosed its first patient in a clinical trial of its lead drug candidate, INT2104, an in vivo CAR T cell therapy that targets B-cell malignancies. If successful, the treatment has the potential to be faster, less expensive, and more accessible to patients than other currently available ex vivo CAR T cell therapies. Read more here and here.